Iatrogenic Cushing's Syndrome Post Intralesional Triamcinolone Acetonide in Oral Submucous Fibrosis: 2 Case Reports
October 2023
in “
BMC oral health
”
Studysummary This study reported that while Intralesional Triamcinolone Acetonide injections effectively improved mouth opening in patients with Oral Submucous Fibrosis, it also led to symptoms of Cushing's Syndrome, highlighting the need for careful monitoring of adverse effects. Our plain-language summary of this paper — not a Tressless recommendation.
This document reports on two cases of iatrogenic Cushing’s syndrome following intralesional triamcinolone acetonide (TAC) treatment for oral submucous fibrosis (OSMF). A 44-year-old female and a 40-year-old male, both diagnosed with OSMF, showed significant improvement in mouth opening after TAC injections. However, they developed symptoms of Cushing’s syndrome, such as facial rounding, buffalo hump, uneven hair growth, and lower extremity swelling. Elevated cortisol levels confirmed the diagnosis, leading to the discontinuation of TAC. The report underscores the effectiveness of TAC in treating OSMF but highlights the need for careful monitoring of potential adverse effects due to high dosage or frequency.
